Department of Product Safety, German Federal Institute for Risk Assessment (BfR), Thielallee 88-92, 14195 Berlin, Germany.
Cell Mol Life Sci. 2012 Mar;69(5):763-81. doi: 10.1007/s00018-011-0846-8. Epub 2011 Oct 14.
Contact allergies are complex diseases, and one of the important challenges for public health and immunology. The German 'Federal Institute for Risk Assessment' hosted an 'International Workshop on Contact Dermatitis'. The scope of the workshop was to discuss new discoveries and developments in the field of contact dermatitis. This included the epidemiology and molecular biology of contact allergy, as well as the development of new in vitro methods. Furthermore, it considered regulatory aspects aiming to reduce exposure to contact sensitisers. An estimated 15-20% of the general population suffers from contact allergy. Workplace exposure, age, sex, use of consumer products and genetic predispositions were identified as the most important risk factors. Research highlights included: advances in understanding of immune responses to contact sensitisers, the importance of autoxidation or enzyme-mediated oxidation for the activation of chemicals, the mechanisms through which hapten-protein conjugates are formed and the development of novel in vitro strategies for the identification of skin-sensitising chemicals. Dendritic cell cultures and structure-activity relationships are being developed to identify potential contact allergens. However, the local lymph node assay (LLNA) presently remains the validated method of choice for hazard identification and characterisation. At the workshop the use of the LLNA for regulatory purposes and for quantitative risk assessment was also discussed.
接触过敏是一种复杂的疾病,也是公共卫生和免疫学面临的重要挑战之一。德国“联邦风险评估研究所”举办了一场“接触性皮炎国际研讨会”。该研讨会的范围是讨论接触性皮炎领域的新发现和新进展。这包括接触过敏的流行病学和分子生物学,以及新的体外方法的发展。此外,还考虑了旨在减少接触敏化剂暴露的监管方面。据估计,有 15%至 20%的普通人群患有接触过敏症。工作场所暴露、年龄、性别、消费产品的使用和遗传易感性被确定为最重要的风险因素。研究亮点包括:对接触敏化剂免疫反应的理解取得进展,自动氧化或酶介导的氧化对化学物质激活的重要性,半抗原-蛋白缀合物形成的机制以及用于识别皮肤致敏化学物质的新型体外策略的发展。正在开发树突状细胞培养物和构效关系,以识别潜在的接触过敏原。然而,目前局部淋巴结检测(LLNA)仍然是用于危害识别和特征描述的首选验证方法。在研讨会上,还讨论了 LLNA 在监管用途和定量风险评估中的应用。